Investigating the effects of nicotinamide riboside on metabolism and cognition in Alzheimer's patients
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia
This study is looking at how taking a supplement called nicotinamide riboside might help improve energy use in the body, reduce stress on cells, and boost thinking skills in people with mild cognitive impairment or early Alzheimer's, to see if it can help support better brain health as we age.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mclean Hospital NIH-funded |
| Lab location | 1 site (Belmont, United States) |
| Project ID | NIH-10866403 on NIH RePORTER |
What this research studies
This research explores how orally administered nicotinamide riboside (NR) can impact bioenergetic metabolism, oxidative stress, and cognitive function in individuals with mild cognitive impairment and mild Alzheimer's dementia. The study aims to understand the role of NR in enhancing mitochondrial function and potentially reversing age-related cognitive decline. Participants will receive NR supplements, and researchers will monitor changes in their metabolic processes and cognitive abilities over time. This approach is based on the premise that improving mitochondrial health may lead to better brain function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mild cognitive impairment or mild Alzheimer's dementia, particularly those over the age of 45.
Not a fit: Patients with advanced Alzheimer's disease or other severe neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve cognitive function and quality of life for patients with Alzheimer's disease.
How similar studies have performed: While there have been numerous clinical trials investigating nicotinamide riboside, this specific approach focusing on Alzheimer's disease is relatively novel.
Where this research is happening
Belmont, United States
- Mclean Hospital — Belmont, United States (Active)
Researchers
- Principal investigator: Du, Fei — Mclean Hospital
- Study coordinator: Du, Fei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.